Dec 3, 2019 at 8:00 AM EST
RENEW-Part 1 Presentation 570.8 KB
Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidates are first-in-class treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.
Investor Relations Contact
Scott Solomon
Sharon Merrill Associates
Senior Vice President
EMAIL: ALDX@investorrelations.com
PHONE: 857-383-2409